- Report
- October 2024
- 100 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- April 2025
- 250 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 288 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- July 2024
- 200 Pages
Global
From €4433EUR$4,949USD£3,779GBP
- Report
- May 2025
- 197 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 184 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 191 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 180 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 193 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 198 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 187 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- March 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- April 2025
- 250 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 181 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 142 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 146 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 193 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- May 2025
- 183 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- July 2024
- 200 Pages
Global
From €4433EUR$4,949USD£3,779GBP

Interleukin inhibitors are a type of immune disorder drug used to treat a variety of conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the action of interleukins, which are proteins that play a role in inflammation and the body's immune response. Interleukin inhibitors can be used alone or in combination with other drugs to reduce inflammation and improve symptoms.
The interleukin inhibitor market is a rapidly growing segment of the immune disorder drug market. It is expected to continue to grow as more treatments become available and as the demand for treatments for immune-related conditions increases.
Some of the major companies in the interleukin inhibitor market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, and Pfizer. These companies are actively researching and developing new treatments for immune-related conditions. Show Less Read more